Right Ventricular Dysfunction

Rheumatic Heart Disease

Right Ventricular Echo Assessment in Mitral Valve Replacement

Right Ventricular Function After Mitral Valve Replacement in Rheumatic Heart Disease Patients With Pulmonary Hypertension: Short Term Follow up

change in TAPSE (Tricuspid annular plane systolic excursion )

TDI (Tissue doppler imaging) across the lateral tricuspid annulus : peaked S' velocity

change in RVFAC : Right ventricular calculated ejection fraction by mean of change in RV systolic and diastolic volumes

PASP measured by CW doppler across tricusped valve regurgetant jet

The evaluation of reverse right ventricle (RV) remodelling, assessed as reduction/modification of the end diastolic and end systolic RV diameters with respect to pre-surgery

Percentage of patients with moderate to severe TR at 3 months after surgery

Modification of NYHA class at 3 months after surgery

Mortality within hospital stay or 3 months postoperative.

Ahmed M. Nasr

Assistant Lecturer Cardiothoracic surgery

Assiut University

Non ST Segment Elevation Myocardial Infarction

Unstable Angina

Drugs will be provided by the sponsor to the study's patients on the reference presentation: 40 mg/0.4mL, 60 mg/0.6 mL and 80 mg/0.8 mL (solution for injection of enoxaparin sodium, 1 mg/ kg Sanofi-Aventis) or Eurofarma enoxaparin sodium (1 mg/ kg). The patients will use the drug corresponding to the arm of the study to which they were allocated. The drug administration must be performed through subcutaneous via on the dose of 1 mg/kg every 12 hours for at least 2 days and kept until the patient is discharged.

Enoxaparin

Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation

A Multicenter, Randomized, Open-label, Non-inferiority Phase III Study, Between Low-Molecular Weight Heparins, Versa® (Enoxaparin - Eurofarma) and Clexane® (Enoxaparin - Sanofi-Aventis), in Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation.

The study primary objective aims at evaluating the enoparaxin sodium (Eurofarma) effectiveness and safety on the treatment of patients with NSTE-ACS and high-risk ones, regarding the Sanofi-Aventis enoxaparin sodium. The primary endpoint will be the frequency of death and infarction within 30 days after the admission in emergency.

The secondary endpoints considered for the study are:
Negative endpoints associated to ACS (shock, pulmonary congestion, arrhythmias, congestive heart failure, hemodynamic instability and reinfarction) during 30 days after the beginning of the treatment.
Frequency of coronary angioplasty or surgical revascularization procedures; Rate of major bleeding during hospitalization according to TIMI criteria ; Incidence of hemotransfusion in the 30 days after the inclusion on the study.

Eurofarma Laboratorios S.A.

Mitral Valve Regurgitation

Left Ventricular Dysfunction

Heart Failure

Mitral Insufficiency

Mitral Incompetence

Ischemic Heart Disease

Ventricular reshaping to treat functional mitral insufficiency

mitral valve insufficiency/drudzis

Right Ventricular Echo Assessment in Mitral Valve Replacement

Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation

VIVID - Valvular and Ventricular Improvement Via iCoapsys Delivery - Feasibility Study

Vispilnīgākā ārstniecības augu datu bāze, kuru atbalsta zinātne